This document summarizes a study on triggers for disruption in the dominant logic and business model of the pharmaceutical industry. The study used expert interviews and case studies of bioinformatics companies attempting to disrupt the industry. The dominant logic of the industry focuses on product development through networks and alliances controlled by large firms. Emerging business models from bioinformatics companies represent a seed for evolving this logic. The study found that technological discontinuities can trigger disruption when they enable new business models, rather than just new technologies. Business model innovations may challenge the dominant industry logic as much as technological changes alone.